Lemborexant 15 mg Safety Assessment
Lemborexant 15 mg is not an FDA-approved dose and should not be used. The FDA-approved doses are 5 mg and 10 mg only, with 10 mg being the maximum recommended dose 1.
FDA-Approved Dosing
The available evidence clearly establishes that:
- Approved doses: 5 mg and 10 mg only
- Maximum dose: 10 mg
- No 15 mg formulation exists in the approved prescribing information
The 2017 American Academy of Sleep Medicine guidelines reference suvorexant (a related orexin receptor antagonist) at doses of 10,15/20, and 20 mg 2, but lemborexant is a different medication with different dosing parameters.
Safety Profile at Approved Doses
At the FDA-approved doses (5 mg and 10 mg), lemborexant demonstrates:
Efficacy:
- Reduces sleep onset latency by 9-13 minutes 3
- Decreases wake after sleep onset by 20-22 minutes 3, 4
- Improves sleep efficiency by 6-7% 3, 4
Safety:
- Well-tolerated with no clinically relevant next-morning residual sleepiness at doses through 10 mg 5
- Most common adverse effect is somnolence (approximately 5-fold higher than placebo) 3
- Treatment-emergent adverse events occur but are generally mild 3, 4
- Even in massive overdose (720 mg), only mild sedation occurred, suggesting a favorable safety margin 6
Critical Drug Interaction
Avoid concomitant use with moderate CYP3A4 inhibitors (such as fluconazole), which increase lemborexant exposure by 4.2-fold and significantly elevate somnolence risk 1.
Clinical Recommendation
Use lemborexant 5 mg or 10 mg only. If 10 mg is insufficient for symptom control, consider alternative insomnia treatments rather than exceeding the maximum approved dose. The 5 mg dose may be preferable in patients at higher risk for daytime somnolence 3.